Baar, Switzerland
Bluestone Pharma, established in 2013 and headquartered in Switzerland, is a pioneer in the biotechnology and health care sectors. The company focuses on leveraging the human oral microbiome to enhance health outcomes, positioning itself as a leader in probiotic innovation.
Under their slogan, "Expert Pioneers in Human Oral Microbiome", Bluestone Pharma commits to the development and manufacture of probiotic formulas using proprietary technology. These innovations are aimed at providing their partners with a competitive advantage in the probiotic market.
The company's flagship product, Bactoblis®, stands as the most clinically tested probiotic for recurrent respiratory infections in children and teenagers, supported by over 30 clinical studies. Since its inception, the company has expanded its reach to 25 countries, with healthcare professionals prescribing over 200 million doses of their products globally.
Currently, the company has not recorded any recent investment activities, presenting a potential opportunity for investors to engage with a well-established player in an expanding market.
